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Allergy: From History to Today
In Allergology International (AI ) Vol. 62, No.1, we
have 3 Review Articles, 13 Original Articles, and 4
Letter-to-the-Editor reports. AI is publishing theme is-
sues that include reviews in important fields of cur-
rent research activity written by eminent experts.
The theme of this issue is “Allergy: From History to
Today.”
In the first review article of this year, entitled “Mast
Cells and IgE: From History to Today,” I (H.S. one of
the authors) would like to introduce the history of re-
search regarding the role of mast cells and IgE in al-
lergic diseases to the young investigators.1
I had been serving as a postdoctoral fellow for mast
cell research under supervision of Prof. Teruko Ishi-
zaka and Prof. Kimishige Ishizaka at Johns Hopkins
University from 1986 to 1988. During discussion
about the research, Dr. Teruko Ishizaka (Terry) used
to tell me about the history of research regarding the
role of mast cells and IgE at her office. Unfortunately,
Terry has been ill and hospitalized for more than 10
years until now. So, I started to write this review arti-
cle, by tracing my memory about Terry’s tale. Then, I
consulted by e-mail to Dr. Kimishige Ishizaka (Kimi)
as to whether the content is accurate. Kimi soon sent
it back to me by making some important corrections
especially regarding discoveries of IgE and the recep-
tor, while taking care of Terry in her room of the hos-
pital.
As described in this review, IgE-dependent mast
cell activation and allergic reactions have been re-
vealed thoroughly in the past half century, since IgE
was discovered. However, it seems that the mecha-
nisms involved in non-IgE-mediated allergic diseases
or non-IgE-mediated phase of IgE-mediated diseases
are almost left unsolved and are waiting for devoted
investigators to reveal it.
Interleukin (IL-)33 is crucially involved in non-IgE-
mediated phase of IgE-mediated diseases. Nakae et
al.2 summarized the recent topics on the role of IL-33
in allergy, by focusing on its role in such innate-type
immune cells as mast cells, basophils and natural
helper cells. Tamari et al.3 summarized the historical
points of view and recent topics on genome-wide as-
sociation studies (GWAS), which is a comprehensive
and unbiased approach to identify susceptibility loci
for diseases, for allergic diseases. Candidate genes in
the susceptibility loci suggest roles for epithelial bar-
rier functions, innate-adaptive immunity, IL-1 family
signaling, regulatory T cells and the vitamin D path-
way in the pathogenesis of allergic diseases. Interest-
ingly, the IL1RL1 (the receptor for IL-33), HLA, IL13
and C11orf30 regions are overlapping susceptibility
loci among atopic dermatitis and asthma or allergic
rhinitis.
Related to these thematic review articles, Mato, et
al.4 reported that IL-33 levels are increased in sera
and bronchial lavage fluids in the patients with acute
eosinophilic pneumonia, where antigen-specific IgE
antibody is unnecessary. Like IL-33, thymic stromal
lymphopoietin (TSLP) is also derived from epithelial
barrier tissue, crucially involved in allergic inflamma-
tion and its gene polymorphism is frequently identi-
fied to be associated with various allergic dis-
eases.3,5,6 Iijima et al.7 suggest that TSLP may cause
asthma by promoting innate allergic responses to in-
door allergens, by analyzing such clinical and
genomic markers as specific IgE antibodies obtained
from approximately 2,000 Japanese subjects.
As written in Instructions for Authors, such clinical
trials as pharmacological interventions should be pre-
registered to a public registry approved by WHO, for
example, www.clinicaltrials.gov, or www.umin.ac.jp
ctrindex-j.htm. This should be applied even to other
interventional clinical studies in order to preclude
post-hoc analysis where the authors can even select a
single significant result by coincidence among vari-
ous results. In this sense, the clinical trial reported by
Katsunuma et al. , 8 where clinical trial registration
number and endpoints are clearly specified, may be
an ideal model.
Hirohisa Saito
Editor-in-Chief, Allergology International
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